Home » SGX Submits IND for Cancer Candidate
SGX Submits IND for Cancer Candidate
The FDA has received SGX Pharmaceuticals’ investigational new drug (IND) application for SGX523, a treatment for patients with solid tumors
The company expects to begin Phase I trials with SGX523 in solid tumor cancer patients in early 2008.
Mike Grey, SGX’s president and CEO, said the application’s submission comes a quarter earlier than anticipated.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May